Effectiveness of Yisui Granules on low/intermediate risk type Ⅰ myelodysplastic syndromes: clinical trial protocol design features and evaluation
LI Ruibai1 DONG Qing1 LYU Peng1 HU Xiaomei2 YANG Xiupeng2 HOU Li1 ZHANG Yayue1
1.Department of Hematology and Oncology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China;
2.Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China
Abstract:This paper introduces the clinical trial protocol of Yisui Granules in the treatment of low/intermediate risk type Ⅰ myelodysplastic syndromes, and evaluates its clinical practicability, scientific nature, program design features, which reflects the international synchronization and recognition of traditional Chinese medicine (TCM) theories and western medicine laboratory indicators, and lays a foundation for future clinical promotion and industry recognition. A prospective and pragmatic randomized controlled trial is used, and objective evaluation of the clinical efficacy of Yisui Granules in the treatment of low/intermediate risk type Ⅰ myelodysplastic syndromes is made by good clinic practice (GCP). By using TCM theories and analyzing relevant indicators, the clinical symptoms and signs are combined with modern laboratory indicators, to explore the clinical efficacy and effect mechanism of Yisui Granules in the treatment of low/intermediate risk type Ⅰ myelodysplastic syndromes from the aspects of quality of life and objective curative effect.
[1] 胡凯文,孙颖立,乐兆升,等.益气养阴活血治疗骨髓增生异常综合征临床研究[J].北京中医药大学学报,1994, 17(2):39-41.
[2] 陈信义,肖萍,胡凯文,等.益髓颗粒剂改善骨髓巨核系病态造血的临床研究[J].北京中医药大学学报,1998,21(1):44-46.
[3] 李冬云,陈信义.益髓颗粒剂降低骨髓增生异常综合征感染率的临床研究[J].中国医药学报,1998,13(6):27-29.
[4] 陈信义,韦云,苏伟,等.益髓灵对MDS患者血淋巴细胞周期影响的初步研究[J].中国中医基础理论杂志,1995, 1(1):47-48.
[5] 陈信义,韦云,苏伟,等.流氏细胞仪分析益髓灵对MDS患者T细胞亚群的影响[J].中国中医基础医学杂志,1995, 1(3):32-33.
[6] Rollison DE,Howlader N,Smith MT,et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States 2001-2004 using data from NAACCR and SEER programs [J]. Blood,2008,112(1):45-52.
[7] 王蔚.成人骨髓增生异常综合征和再生障碍性贫血的发病率和预后研究[D].上海:复旦大学,2010.
[8] 叶丽,佟红艳.骨髓增生异常综合征的治疗现状及进展[J].临床荟萃,2014,29(10):1095-1099.
[9] 吴萍.去甲基化药物治疗较高危骨髓增生异常综合征的疗效预测及耐药相关机制的研究[D].广州:南方医科大学,2016:1-78.
[10] Santini V. Novel therapeutic strategies:hypomethylating agents and beyond [J]. Hematol Am Soc Hematol Educ Program,2012,11(1):65-73.
[11] 李冬云,陈信义.中医药治疗骨髓增生异常综合征临床研究进展[J].医学综述,1996,2(8):425-426.
[12] 李洁,陈信义.陈信义教授治疗骨髓增生异常综合征的思路[J].成都中医药大学学报,2012,35(4):68-69.
[13] Vanlet P,Horny HP,Bennet JM,et al. Definitions and standards in the diagnosis and treatment of myelodysplastic sydromes:Consensus statements and report from a working conference [J]. Leuk Res,2007,31(6):727-736.
[14] Sabattini E,Bacci F,Sagramoso C,et al. WHO classification of tumours of haematopoietic and lymphoid tissues in2008:an overview [J]. International Agency for Research on Cancer,2008,102(3):83-87.
[15] Vardiman JW,Harris NL,Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms [J]. Blood,2002,1000(7):2292-2302.
[16] 张之南,沈悌.血液病诊断及疗效标准[S].3版.北京:科学出版社,2007:161.
[17] Van Gerpen RE,Becker BJ. Development of Evidence-Based Exercise and Education Cancer Recovery Program [J]. Clin J Oncol Nurs,2013,17(5):539-543.
[18] 李娜.复方阿胶浆治疗癌因性疲乏的临床观察[D].北京:北京中医药大学,2012.
[19] 张洪钧,宋玉华,孙颖立,等.益髓灵初提物对白血病巨核细胞系HI-Meg增殖与分化影响的研究[J].中国组织化学与细胞化学杂志,1996,5(4):483-488.
[20] 张冬霞,云雁.多疗程不同方案地西他滨治疗老年骨髓增生异常综合征转化急性白血病1例并文献复习[J].中国现代医生,2017,55(5):124-126.
[21] 夏芸芸,苏晓琳,姜巍,等.中药治疗骨髓增生异常综合征临床疗效Meta分析[J].世界中医药,2016,11(2):351-354.
[22] 张洪钧,陈信义,宋玉华,等.益髓灵对白血病巨核细胞系HI-Meg基因表达影响的初步研究[J].中国中医基础医学杂志,1996,2(1):43-44.
[23] 陈信义,邵德彬,赵立业,等.益髓灵氯仿提取物诱导HL60细胞凋亡的初步研究[J].中医杂志,1999,40(4):235-236,245.
[24] 彭丽萍.地西他滨治疗伴有DNMT3A基因突变的骨髓增生异常综合征的临床研究[J].中国当代医药,2017, 24(33):45-47.
[25] 高利顺,孟素萍,陈信义,等.益髓灵诱导HL-60及脐带血单个核细胞凋亡比较研究[J].中国医药学报,2000, 15(5):26-28,82.
[26] 青雪梅,房繁恭,刘保延,等.实用性随机对照试验及其方法学特征思考[J].北京中医药大学学报,2008,31(1):14-18.
[27] 张凤玲,韩丽沙.癌因性疲乏的护理研究进展[J].中华护理杂志,2008,43(3):271-274.
[28] 赵攀,邓中阳,王明镜,等.骨髓增生异常综合征的中医辨证论治[J].世界中医药,2017,12(10):2339-2342, 2346.
[29] 彭莉.地西他滨联合预激方案治疗老年骨髓增生异常综合征的临床效果分析[J].中国当代医药,2017,24(18):25-27.
[30] Annunziata MA,Muzzati B,Mella S,et al. The revised Piper fatigue scald for Italian cancer patients:validation study [J]. Tumori,2010,96(2):276-281.